Organokines and Liver Enzymes in Adolescent Girls with Polycystic Ovary Syndrome During Randomized Treatments

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 May 31

PMID 38818508

Authors

Cristina Garcia-Beltran

Marion Peyrou

Artur Navarro-Gascon

Abel Lopez-Bermejo

Francis de Zegher

Francesc Villarroya

Lourdes Ibanez

Affiliations

Soon will be listed here.

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is often associated with metabolic-associated fatty liver disease (MAFLD). MAFLD has been associated with altered hepatic function, systemic dysmetabolism, and abnormal circulating levels of signaling molecules called organokines. Here, we assessed the effects of two randomized treatments on a set of organokines in adolescent girls with PCOS and without obesity, and report the associations with circulating biomarkers of liver damage, which were assessed longitudinally in the aforementioned studies as safety markers.

Materials And Methods: Liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT)] were assessed as safety markers in previous randomized pilot studies comparing the effects of an oral contraceptive (OC) with those of a low-dose combination of spironolactone-pioglitazone-metformin (spiomet) for 1 year. As a endpoint, the organokines fibroblast growth factor-21 (FGF21), diazepam-binding protein-1 (DBI), and meteorin-like protein (METRNL) were assessed by ELISA after 6 months of OC (N = 26) or spiomet (N = 28). Auxological, endocrine-metabolic, body composition (using DXA), and abdominal fat partitioning (using MRI) were also evaluated. Healthy, age-matched adolescent girls (N = 17) served as controls.

Results: Circulating ALT and GGT levels increased during OC treatment and returned to baseline concentrations in the post-treatment phase; in contrast, spiomet treatment elicited no detectable changes in ALT and GGT concentrations. In relation to organokines after 6 months of treatment, (1) FGF21 levels were significantly higher in PCOS adolescents than in control girls; (2) DBI levels were lower in OC-treated girls than in controls and spiomet-treated girls; and (3) no differences were observed in METRNL concentrations between PCOS girls and controls. Serum ALT and GGT levels were directly correlated with circulating METRNL levels only in OC-treated girls (R = 0.449, P = 0.036 and R = 0.552, P = 0.004, respectively).

Conclusion: The on-treatment increase in ALT and GGT levels occurring only in OC-treated girls is associated with circulating METRNL levels, suggesting enhanced METRNL synthesis as a reaction to the hepatic changes elicited by OC treatment.

Clinical Trial Registration: https://doi.org, identifiers 10.1186/ISRCTN29234515, 10.1186/ISRCTN11062950.

Citing Articles

Type 2 Diabetes Mellitus and Cardiometabolic Prospects: A Rapid Narrative Review.

Chowdhury K, Sinha S, Ahmad R, Lugova H, Mehta M, Kumar S Cureus. 2024; 16(7):e65808.

PMID: 39092382 PMC: 11293072. DOI: 10.7759/cureus.65808.

References

Bril F, Ezeh U, Amiri M, Hatoum S, Pace L, Chen Y . Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 109(1):10-24. PMC: 10735305. DOI: 10.1210/clinem/dgad356. View

Teede H, Tay C, Laven J, Dokras A, Moran L, Piltonen T . Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10):2447-2469. PMC: 10505534. DOI: 10.1210/clinem/dgad463. View

Wang W, Shui L, Liu Y, Zheng M . C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases. Front Genet. 2021; 12:598855. PMC: 7884772. DOI: 10.3389/fgene.2021.598855. View

Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, Sabiote C, Sena E, Banares J . Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression. J Clin Med. 2023; 12(3). PMC: 9917911. DOI: 10.3390/jcm12030856. View

de Zegher F, Diaz M, Villarroya J, Cairo M, Lopez-Bermejo A, Villarroya F . The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci Rep. 2021; 11(1):7018. PMC: 8007831. DOI: 10.1038/s41598-021-86317-9. View

Ibanez L, Diaz M, Garcia-Beltran C, Malpique R, Garde E, Lopez-Bermejo A . Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome. J Endocr Soc. 2020; 4(5):bvaa032. PMC: 7182125. DOI: 10.1210/jendso/bvaa032. View

Stefan N, Schick F, Birkenfeld A, Haring H, White M . The role of hepatokines in NAFLD. Cell Metab. 2023; 35(2):236-252. PMC: 10157895. DOI: 10.1016/j.cmet.2023.01.006. View

Wolf W, Wattick R, Kinkade O, Olfert M . Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J Environ Res Public Health. 2018; 15(11). PMC: 6266413. DOI: 10.3390/ijerph15112589. View

Ibanez L, de Zegher F . Adolescent PCOS: a postpubertal central obesity syndrome. Trends Mol Med. 2023; 29(5):354-363. DOI: 10.1016/j.molmed.2023.02.006. View

10.

Falzarano C, Lofton T, Osei-Ntansah A, Oliver T, Southward T, Stewart S . Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021; 107(1):258-272. DOI: 10.1210/clinem/dgab658. View

11.

Ibanez L, Del Rio L, Diaz M, Sebastiani G, Pozo O, Lopez-Bermejo A . Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. J Adolesc Health. 2017; 61(4):446-453. DOI: 10.1016/j.jadohealth.2017.04.010. View

12.

Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay C . Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023; 189(1):S1-S16. DOI: 10.1093/ejendo/lvad082. View

13.

Motino O, Lambertucci F, Anagnostopoulos G, Li S, Martins I, Kroemer G . Cardio-, hepato- and pneumoprotective effects of autophagy checkpoint inhibition by targeting DBI/ACBP. Autophagy. 2022; 19(5):1604-1606. PMC: 10240994. DOI: 10.1080/15548627.2022.2131241. View

14.

Grander C, Grabherr F, Enrich B, Meyer M, Mayr L, Schwarzler J . Hepatic Meteorin-like and Krüppel-like Factor 3 are Associated with Weight Loss and Liver Injury. Exp Clin Endocrinol Diabetes. 2021; 130(6):406-414. DOI: 10.1055/a-1537-8950. View

15.

Watt M, Miotto P, De Nardo W, Montgomery M . The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019; 40(5):1367-1393. DOI: 10.1210/er.2019-00034. View

16.

Chung H, Choi K . Organokines in disease. Adv Clin Chem. 2020; 94:261-321. DOI: 10.1016/bs.acc.2019.07.012. View

17.

Shorakae S, Jona E, de Courten B, Lambert G, Lambert E, Phillips S . Brown adipose tissue thermogenesis in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 90(3):425-432. DOI: 10.1111/cen.13913. View

18.

Diaz M, Gallego-Escuredo J, de Zegher F, Villarroya F, Ibanez L . Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess. Diabetes Metab. 2015; 42(3):196-9. DOI: 10.1016/j.diabet.2015.10.004. View

19.

Liu D, Gao X, Pan X, Zhou T, Zhu C, Li F . The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome. BMC Med. 2023; 21(1):62. PMC: 9940436. DOI: 10.1186/s12916-023-02775-0. View

20.

Spremovic Radenovic S, Pupovac M, Andjic M, Bila J, Sreckovic S, Gudovic A . Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). Biomedicines. 2022; 10(1). PMC: 8773533. DOI: 10.3390/biomedicines10010131. View